孕期母亲使用对乙酰氨基酚与子代自闭症谱系障碍及注意缺陷/多动障碍风险:系统综述的伞状综述
该伞状综述纳入9篇系统综述(含40项研究),评估孕期母亲使用对乙酰氨基酚与子代自闭症及注意缺陷/多动障碍(ADHD)风险的证据质量与偏倚。多数综述报告可能至强关联,但7篇提示因偏倚和混杂需谨慎解读,AMSTAR 2评价置信度为低至极低。仅1篇综述纳入2项采用同胞对照分析的研究,全队列中升高的风险在同胞对照分析中未持续存在。结论认为现有证据未明确显示孕期使用对乙酰氨基酚与子代自闭症或ADHD相关。
要点
- 9篇系统综述(40项研究)报告孕期对乙酰氨基酚使用与子代自闭症或ADHD的可能至强关联。
- 7篇综述建议谨慎解读,因纳入研究存在偏倚和混杂风险;AMSTAR 2置信度低至极低。
- 仅2项研究采用同胞对照分析,全队列中升高的风险在同胞对照分析中未持续存在。
核心结论
- 现有证据未明确显示孕期母亲使用对乙酰氨基酚与子代自闭症或ADHD相关。
研究设计与样本
- 系统综述的伞状综述,检索Medline、Embase、PsycINFO、Cochrane系统综述数据库、灰色文献、Epistemonikos及纳入研究参考文献,检索时间自建库至2025年9月30日。
- 纳入报告孕期母亲使用对乙酰氨基酚与子代自闭症或ADHD诊断的系统综述,涵盖随机试验及队列、病例对照或横断面研究。
- 共纳入9篇综述(40项研究),其中4篇进行了Meta分析;纳入综述中原始研究的重叠度很高(校正覆盖面积23%)。
主要发现
- 9篇综述报告孕期母亲对乙酰氨基酚摄入与子代自闭症或ADHD或两者存在可能至强的关联。
- 7篇综述建议谨慎解读结果,因纳入研究存在潜在偏倚和混杂风险。
- 基于AMSTAR 2标准,综述结论的置信度为低(2篇)至极低(7篇)。
- 仅1篇综述纳入2项通过同胞对照分析适当调整家族因素和未测量混杂的研究;全队列分析中自闭症风险升高(1项研究,HR 1.05,95%CI 1.02至1.08),ADHD风险升高(2项研究,HR 1.07,95%CI 1.05至1.10;HR 2.02,95%CI 1.17至3.25),但这些风险在同胞对照分析中未持续存在:自闭症(HR 0.98,95%CI 0.93至1.04),ADHD(HR 0.98,95%CI 0.94至1.02;HR 1.06,95%CI 0.51至2.05)。
关键数值与推荐
- AMSTAR 2评价置信度:低(2篇综述)至极低(7篇综述)。
- 纳入综述中原始研究的校正覆盖面积为23%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 7篇综述建议谨慎解读结果,因纳入研究存在潜在偏倚和混杂风险。
- 基于AMSTAR 2标准,综述结论的置信度为低(2篇)至极低(7篇)。
- 纳入综述中原始研究的重叠度很高(校正覆盖面积23%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the quality, biases, and validity of evidence on maternal paracetamol (acetaminophen) use during pregnancy and the risk of autism spectrum disorder (referred to as autism) and attention deficit/hyperactivity disorder (ADHD) in offspring. DESIGN: Umbrella review of systematic reviews. DATA SOURCES: Medline, Embase, PsycINFO, and the Cochrane Database of Systematic Reviews, along with grey literature, Epistemonikos, and the reference lists of included studies (inception to 30 September 2025). INCLUSION CRITERIA: Systematic reviews of randomised trials and cohort, case-control, or cross sectional studies that reported maternal paracetamol use during pregnancy and the diagnosis of autism or ADHD in offspring. Details of the primary studies included in the reviews are reported, including adjustments for key confounders (maternal characteristics, indication for paracetamol use, and familial factors) and unmeasured confounders and ascertainment of outcomes. RESULTS: Nine reviews (40 studies) reporting on autism (six studies) and ADHD (17 studies) in offspring were included. Four reviews undertook meta-analysis. The overlap of primary studies included in the reviews was very high (corrected covered area 23%). The reviews reported a possible to strong association between maternal paracetamol intake and autism or ADHD or both in offspring. Seven of the nine reviews advised caution when interpreting the findings owing to the potential risk of bias and confounding in the included studies. Confidence in the findings of the reviews was low (two reviews) to critically low (seven reviews) based on the AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews) criteria. Only one review included studies (n=2) reporting autism and ADHD in offspring that appropriately adjusted for familial factors and unmeasured confounding through sibling controlled analyses. In both studies, the increased risk of autism in offspring (one study, hazard ratio 1.05, 95% confidence interval 1.02 to 1.08) and ADHD (two studies, 1.07, 1.05 to 1.10 and 2.02, 1.17 to 3.25 ) observed in the whole cohort analyses did not persist in sibling controlled analyses for autism (0.98, 0.93 to 1.04) and ADHD (0.98, 0.94 to 1.02 and 1.06, 0.51 to 2.05). CONCLUSION: Existing evidence does not clearly link maternal paracetamol use during pregnancy with autism or ADHD in offspring. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420251154052.
引用
- Sheikh J, Allotey J, Sobhy S, et al. Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit/hyperactivity disorder in offspring: umbrella review of systematic reviews. BMJ. 2025. PMID: 41207796. doi:10.1136/bmj-2025-088141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。